Genetic testing has become a central eligibility mechanism in modern clinical trials. As genetically stratified programs expand across rare disease and oncology, the regulatory frameworks governing how tests are validated, approved, and used are increasingly consequential for sponsors operating across multiple jurisdictions. As eligibility criteria increasingly depend on confirmed genetic variants, the regulatory requirements governing testing validity, laboratory compliance, and data handling have become a material operational consideration for sponsors designing and executing genetically stratified trials.
As the role of genetic testing in healthcare grows, regulatory oversight is intensifying across multiple dimensions. This includes device-level frameworks such as Food and Drug Administration (FDA) approval in the United States, UKCA marking in the United Kingdom, and CE marking in Europe. It also extends to broader legislative protections, including laws governing laboratory standards, patient privacy, and genetic nondiscrimination. For sponsors running genetically stratified trials across multiple geographies, understanding this landscape is essential for compliant study design and execution.
In genetically stratified trials, testing is not an optional or supplementary step. It determines eligibility, defines the patient population, and directly affects both enrollment feasibility and data validity. By analyzing an individual's genetic makeup, researchers can now identify specific genetic variations that influence disease susceptibility, treatment responses, and adverse reactions. Genetic testing reshapes clinical trials in three operationally significant ways: it determines which patients can even enter the eligibility pathway; it defines the stratification logic that underpins study design; and it generates data that affects both regulatory submissions and downstream recontact potential.
As genetically stratified programs scale across phases and geographies, the regulatory and operational requirements around testing will continue to shape how sponsors approach eligibility design, screening workflows, and multi-regional execution.
The regulatory landscape for genetic tests varies between the US, UK, and Europe due to different jurisdictions and regulations.
In the US, the FDA oversees medical device safety and efficacy, including genetic tests. This regulatory system covers both Laboratory Developed Tests (LDTs) and In Vitro Diagnostic (IVD) Tests.
The CMS, or Centers for Medicare & Medicaid Services, also regulates clinical laboratories, including laboratories conducting clinical genetic testing, using the guidelines of the Clinical Laboratory Improvement Amendments (CLIA).
In addition to device and laboratory regulation, sponsors should also account for US legislative requirements that shape how genetic information is collected, protected, and used in research:
The UK has its own regulatory framework post-Brexit, overseen by the Medicines and Healthcare Products Regulatory Agency (MHRA). For genetic testing, the UKCA mark applies to in vitro diagnostic devices (IVDs) and indicates compliance with the UK's medical device regulations, including requirements related to safety, quality, and performance under MHRA oversight. This is important for genetic testing for research as well as direct-to-consumer genetic testing, as both need to meet certain requirements before they can be used by patients or consumers.
For sponsors running multi-country studies with UK sites, the evolving UKCA and CE marking transitional period can create practical differences in which testing kits or platforms can be supplied, what documentation is required, and how vendors are qualified across UK and EU geographies.
In Europe, the CE marking indicates conformity with European Union regulations for medical devices, including genetic tests. The In Vitro Diagnostic Regulation (IVDR) also aims to establish more consistent standards for IVD tests across member states. It requires device manufacturers to conduct clinical performance studies and provide evidence of safety and performance in line with a device’s assigned risk class.
The IVDR replaced the earlier IVDD and introduced a risk-based classification system that moved many genetic tests into higher risk categories, including some companion diagnostics and germline variant detection. Sponsors should verify that their genetic testing partners and laboratories meet current IVDR classification requirements for the tests being used in trial screening or eligibility workflows.
Regulatory requirements for genetic testing are not a background consideration for clinical trials. They shape study design, influence site and vendor selection, affect testing logistics, and can change how sponsors approach participant engagement and consent.
Across jurisdictions, the compliance inputs differ. In the US, sponsors often need to account for FDA oversight, CLIA laboratory requirements, and legislative frameworks such as HIPAA and GINA. In the UK, MHRA oversight and UKCA marking define how IVD devices can be supplied and used. In Europe, the IVDR and CE marking requirements set expectations for evidence and performance based on risk classification.
This means testing workflows designed for one market may not transfer cleanly to another. Differences in device status, laboratory qualification, and documentation requirements can surface as operational friction if they are treated as late-stage compliance checks rather than design constraints.
For sponsors running multi-regional genetically stratified programs, building regulatory awareness into the earliest stages of study planning helps reduce downstream rework and supports more predictable execution.